

First Name (Preferred Name): Encounter number: NH Number: Chart Created: Y/N

Regional Order Set	Date of Birth: Gender: Age: Encounter Type:
_	Responsibility for Payment: PHN:
Adult Febrile Neutropenia	Primary Care Physician/Attending Physician:
	PATIENT LABEL
Allergies: ☐ None known ☐ Unable to obtain	Weight: kg
List with reactions:	Height: cm
 INCLUSION CRITERIA: temperature 38°C or higher *PLUS* ANC less than 1 X 10⁹/L *AND* meets one or more of high risk factors requiring admission (see the content of the content of	see page 3 for high and low risk factors)
1. ADMIT/TRANSFER/DISCHARGE Admit to:	(MRP)
BC Cancer patient? yes no	
If yes: BC Cancer registration #:	(available from oncologist consults via eHealth viewer)
 notify GP oncologist/oncologist (non-urgent) Note: BC Centre for the North oncologist can be contact 	cted Monday to Friday 0830 to 1630 at 250-645-7328
2. DIAGNOSIS	
respiratory peri-an	nd soft tissue nal/rectal
3. CODE STATUS	
 complete 10-111-5171 Medical Orders for Scope of Treatr 	ment (MOST)
4. CONSULTS/REFERRALS: Infectious Diseases Specialist	
5. ACTIVITY: as tolerated other:	
6. DIET/NUTRITION: as tolerated NPO other:	
7. IV FLUIDS: Saline lockat _	
8. LABORATORY	memori. Nedosess in nodis.
 STAT Microbiology: (if not already done) blood cultures from 2 different sites prior to first dose of an (draw from central venous catheter if present; draw from enurinallysis with culture (if indicated) resp panel NAT swab – notify lab that patient is being admit other culture: 	each lumen; label which culture came from which lumen)
• CBC w/Diff • E7 (Na, K, Cl, CO ₂ , Cre, urea, Glu) • Ca, Mg, PO ₄ • C-reactive protein • Serum lactate • LDH, GGT, A • venous blood • total bilirubin	ALP, AST, ALT d gases
Then once daily X 3 days (MRP to reassess): • CBC w/Diff • creatinine	
9. DIAGNOSTIC TESTS Chest X-ray Abdominal X-ray series Other:	



Prescriber signature: College ID: Date: Time: **10-111-5100** (IND - NHTC/RDP/VPM - Rev. - 03/22) **Review by December 31, 2025**



Regional Order Set Adult Febrile Neutropenia **Admission Orders**

Page 2 of 3

Last Name:			
First Name (Prefer	red Name):		
Encounter number	: NH Nu	ımber:	Chart Created: Y/N
Date of Birth:	Gender:	Age:	Encounter Type:
Responsibility for I	Payment:	PHN:	
Primary Care Phys	sician/Attending	Physician:	
PATIENT LABEL			

Allergies: ☐ None known	☐ Unable to obtain	Weight: k	kg
List with reactions:		 Height: ci	m

10. MONITORING

• temp, heart rate, RR, blood pressure, and SpO₂ q1h X 6 hours from initial assessment then MRP to reassess

11. PATIENT CARE

- notify MRP immediately once CBC and ANC results available
- notify MRP if:
 - SBP less than 90 mmHg
 - SpO₂ less than 90% on room air
 - temperature greater than 38°C after initial 24 hours
- initiate 1-11-1-3-700 Protective Precautions Clinical Practice Standard
- complete 10-320-7007 Cytotoxic Drugs Risk Assessment Worksheet (as required)
- review 5-1-3-100 Hazardous Drugs Exposure Control Plan (as required)

12. MEDICATIONS

acetaminophen 650 mg PO g4h prn for significant discomfort due to fever

All ongoing antibiotic therapy to be determined in consultation with the oncologist (if applicable). CARBOplatin or CISplatin chemotherapy increases the risk of renal impairment with use of

valiconfycin of toblamycin.				
Broad Spectrum Antibiotics: piperacillin/tazobactam 4.5 g IV STAT then q6h *OR*				
If severe allergy/anaphylaxis to penicillins: cefTAZidime 2 g IV STAT then q8h *OR*				
If documented or suspected extended spectrum beta lactamase producing organism: meropenem 1 g IV STAT then q8h				
Consider additional anti-pseudomonal coverage, until	vancomycin should be considered in:			

microbiology results available, if:

- hemodynamic instability
- structural lung disease or serious respiratory symptoms
- hospital admission in previous 3 months
- received IV antibiotics in previous 3 months
- history of pseudomonas isolation

ciprofloxacin 400	mg IV	once x	1 dose	then	750	mg
PO bid						

OR

ciprofloxacin 400 mg IV q8h (if unable to take oral)

If quinolone therapy given in previous 3 months:

tobramycin for dosing complete 10-111-5336 **Initiation of Aminoglycosides for Adult Inpatients**

- hemodynamic instability
- clinically suspected central line infection or skin and soft tissue infection
- pneumonia
- positive blood cultures with gram positive organisms not yet identified
- mucositis
- patients who have received **ciprofloxacin** prophylaxis (higher risk for multidrug resistant streptococcus species)
- vancomycin for dosing complete 10-111-5335 **Initiation of Vancomycin for Adult Inpatients**

For guidance on antibiotic duration and persistent infections consult NH Febrile Neutropenia guideline on Firstline (app.firstline.org)

Prescriber signature:	College ID:	Date:	Time:



Regional Order Set Adult Febrile Neutropenia Admission Orders

	Last Name: First Name (Preferred Name):				
	Encounter number:	: NH Number:		Chart Created: Y/N	
	Date of Birth:	Gender:	Age:	Encounter Type:	
	Responsibility for Payment:		PHN:		
	Primary Care Physician/Attending Physician:				
Page 3 of 3	PATIENT LABEL				

Allergies: ☐ None known	☐ Unable to obtain	Weight:	_ kg
List with reactions:		Height:	_ cm

Risk Stratification

High Risk Factors: If patient meets one or more of the below high risk factors - ADMIT

- hemodynamic instability
- inpatient status at time of fever
- temperature greater than 39°C
- severe neutropenia:
- less than or equal to 0.5 x 109/L for more than 7 days
- less than or equal to 0.1 x 109/L
- presence of potential complications, including:
- neurologic changes/confusion
- pneumonia, tachypnea (RR greater than 25 breaths/min)/hypoxia/dyspnea
- new onset of abdominal pain/diarrhea
- severe mucositis
- skin/soft tissue infection
- intravascular catheter infection

- high risk cancer status:
- · uncontrolled, progressive cancer
- hematologic malignancy
- significant comorbid factors:
- age greater than 70, physically/medically frail
- · underlying lung disease
- hepatic insufficiency (liver function tests greater than 5 times normal)
- renal insufficiency (serum creatinine greater than 176 umol/L)
- poor performance status (ECOG greater than 1)
- infectious diseases history:
- taking antibiotics less than 72 hours before presentation
- history of antibiotic resistant bacteria
 - exception: for those with previous history/colonization of MRSA, low risk outpatient management may be considered if patient is clinically stable

Low Risk Factors: Eligible for outpatient treatment if patient meets none of the above high risk factors AND meets following outpatient criteria:

- reliable patient/home support, who can return to facility easily
- can take oral medications
- can be easily contacted for daily assessment
- can be admitted urgently if clinically unwell/unstable

Note: NOT eligible for outpatient treatment if patient cannot meet outpatient criteria, despite having none of the above high risk factors; will need to admit.